伍用参麦注射液治疗慢性再生障碍性贫血30例临床观察

Clinical effects of Shenmai Injection combined with western medicine in 30 patients with chronic aplastic anemia

目的探讨参麦注射液对慢性再生障碍性贫血(CAA)的治疗效果及对红细胞免疫功能的影响。方法55例CAA患者随机分为参麦组30例及对照组20例。对照组采用安雄、环孢素A为主的治疗方案;参麦组在对照组的基础上加用参麦注射液。结果参麦组基本治愈7例,明显缓解10例,进步7例,无效6例,基本治愈缓解率56.7%,总有效率80%;对照组基本治愈4例,明显缓解8例,进步7例,无效6例,基本治愈缓解率48%,总有效率76%;参麦组疗效略优于对照组。参麦组及对照组治疗后红细胞膜C3b受体花环率(C3bRR)均较治疗前显著升高(P<0.01),参麦组患者治疗后C3bRR较对照组有明升高(P<0.05)。结论参麦注射液可能通过调节红细胞免疫功能发挥作用,从而提高CAA的疗效。

Objective To investigate the therapeutic efficacy of Shenmai Injection in patients with chronic aplastic anemia（CAA） and the effect on the immune function of erythrocytes.Methods 55 CAA cases were randomly divided into control group（20 cases,treated with western medicines such as andriol and cyclosporin A） and Shenmai group（30 cases,additional Shenmai Injection was administered in combination with the western medicines in control groups）.The therapeutic efficacy and effect on the erythrocyte immune function were observed.Results In the Shenmai group,7 cases were cured in general,10 cases markedly remitted,7 cases improved and 6 cases failed;the general cure rate was 56.7% and the total efficacy rate was 80%.In the control group,4 cases were cured in general,8 cases remitted,7 cases improved and 6 cases failed;the general cure rate was 48% and the total efficacy rate was 68%.The curative effect in the Shenmai group was significantly better than that in the control group.The C3bRR level in Shenmai group and the control group evidently increased subsequent to the treatment（P〈0.01）.The C3bRR level in the Shenmai group was higher than that in the control group（P〈0.05）.Conclusion Shenmei Injection can improve the therapeutic efficacy of CAA by regulating the immune function of erythrocytes.